Porter Health
Understanding MASLD (Liver Disease)
A Patient's Guide to Metabolic Dysfunction-Associated Steatotic Liver Disease
MASLD stands for Metabolic dysfunction-Associated Steatotic Liver Disease (formerly called NAFLD - Non-Alcoholic Fatty Liver Disease). It's a condition where fat builds up in your liver, even if you drink little or no alcohol.
The Name Change (2023): Medical experts changed the name from "NAFLD" to "MASLD" to better reflect the condition's connection to metabolic health problems like diabetes, obesity, and high cholesterol - not just the absence of alcohol.
How Common Is MASLD?
Connection to Your Overall Health:
MASLD is closely linked to metabolic syndrome - a cluster of conditions that increase your risk for:
MASLD is a spectrum that can progress through several stages. Understanding where you are helps guide treatment and prevention strategies.
Simple Steatosis (Fatty Liver)
Fat accumulation in liver cells, no inflammation
Your liver has extra fat stored in it, but there's no inflammation or damage yet. This is the earliest and most benign stage.
Prognosis: Generally benign. May remain stable for years or decades without progression. Excellent response to lifestyle changes.
MASH (Metabolic dysfunction-Associated Steatohepatitis)
Fat + inflammation in liver cells
The liver has fat AND inflammation. This inflammation can cause liver cell injury and potentially progress to scarring (fibrosis).
Prognosis: Can progress to fibrosis if untreated. Aggressive lifestyle changes and medications (like GLP-1 agonists) can reverse inflammation and prevent progression.
Fibrosis (Liver Scarring)
Scar tissue begins to form in the liver
Chronic inflammation causes scar tissue (fibrosis) to develop. The liver can still function, but scar tissue makes it less efficient. Fibrosis is graded from F0 (none) to F4 (cirrhosis).
Prognosis: Early fibrosis (F1-F2) may be reversible with aggressive intervention. Advanced fibrosis (F3) requires close monitoring and treatment to prevent cirrhosis.
Cirrhosis (Advanced Scarring)
Extensive scar tissue, liver function severely impaired
Advanced scarring has replaced much of the normal liver tissue. The liver struggles to perform its vital functions (detoxification, protein production, clotting factors).
Complications: Portal hypertension, varices (bleeding), ascites (fluid buildup), hepatic encephalopathy (confusion), liver failure.
Prognosis: Irreversible damage, but progression can be slowed. Requires specialist care (hepatologist). May need liver transplant in advanced cases.
Hepatocellular Carcinoma (Liver Cancer)
Increased risk with cirrhosis
People with cirrhosis from MASLD have an increased risk of developing liver cancer (hepatocellular carcinoma, or HCC). Regular screening with ultrasound and blood tests is essential.
Screening: Ultrasound every 6 months + AFP blood test if cirrhosis is present.
Good News: Most people with simple steatosis (Stage 1) will never progress to advanced stages if they address metabolic risk factors through lifestyle changes and medications.
Diagnosing MASLD involves several tests that assess liver fat, inflammation, and scarring. Importantly, liver enzymes may be completely normal even with MASLD.
Liver Enzymes (ALT, AST)
Blood tests that measure liver inflammation
What They Measure:
ALT (alanine aminotransferase) and AST (aspartate aminotransferase) are enzymes released when liver cells are damaged. Elevated levels suggest liver inflammation.
Important Limitation:
Normal liver enzymes do NOT rule out MASLD. Up to 50% of people with MASLD have normal ALT and AST levels, especially in early stages.
Elevated enzymes suggest inflammation, but normal enzymes don't mean your liver is healthy if you have metabolic risk factors.
Understanding Your Numbers:
FIB-4 Score
Non-invasive calculator for liver fibrosis risk
What It Calculates:
The FIB-4 score estimates your risk of having advanced liver fibrosis (scarring) without needing a liver biopsy. It uses your age, platelet count, ALT, and AST levels.
Formula: (Age × AST) / (Platelets × √ALT)
Understanding Your FIB-4 Score:
Why It Matters:
The FIB-4 score helps identify who needs further evaluation with elastography (FibroScan) or referral to a liver specialist. It's a simple, inexpensive first step to assess fibrosis risk.
Advanced Diagnostic Tests
Elastography (FibroScan)
A non-invasive ultrasound-like test that measures liver stiffness (a marker of scarring) and controlled attenuation parameter (CAP), which estimates liver fat content.
Interpretation: Higher stiffness scores indicate more fibrosis. CAP scores >280 dB/m suggest significant fat accumulation.
MRI-PDFF (MRI Proton Density Fat Fraction)
Advanced MRI technique that accurately quantifies liver fat content. Considered the gold standard non-invasive test for measuring liver fat.
Interpretation: PDFF >5% indicates steatosis (fatty liver).
Blood-Based Fibrosis Tests (APRI, ELF)
Blood tests that estimate fibrosis risk using various biomarkers (AST, platelets, hyaluronic acid, etc.).
Use: Often used in combination with FIB-4 to refine fibrosis risk assessment.
Liver Biopsy
The gold standard for diagnosing MASH and staging fibrosis. A small needle is used to remove a tiny sample of liver tissue for microscopic analysis.
When Needed: Reserved for cases where non-invasive tests are inconclusive or when precise staging is needed for treatment decisions.
Imaging (Ultrasound, CT, MRI)
Ultrasound can detect fatty liver (appears brighter on imaging). CT and MRI provide more detailed visualization of liver structure and fat content.
Limitation: Can detect fat but cannot accurately assess inflammation or early fibrosis.
There is no single medication approved specifically for MASLD (yet), but significant progress can be made through lifestyle changes and medications that address underlying metabolic problems.
Weight Loss (Most Important Intervention)
5% Weight Loss
Reduces liver fat content significantly. For most people, this is enough to reverse simple steatosis.
7-10% Weight Loss
Resolves inflammation (MASH) in many people and may reduce early fibrosis.
>10% Weight Loss
Can reverse MASH and improve fibrosis in the majority of people. Most effective treatment for MASLD.
Diet Modifications
Mediterranean Diet
Shown to reduce liver fat, inflammation, and improve metabolic health. Focus on vegetables, fruits, whole grains, olive oil, fish, nuts, and legumes.
Evidence: Multiple studies show Mediterranean diet improves MASLD independent of weight loss.
Avoid Fructose and Sugary Drinks
High fructose intake (especially from soda, juice, sweetened beverages) directly increases liver fat production.
Action: Eliminate sugar-sweetened beverages. Limit added sugars and high-fructose corn syrup.
Limit Refined Carbohydrates
White bread, white rice, pastries, and processed foods spike blood sugar and promote fat storage in the liver.
Action: Choose whole grains (brown rice, quinoa, oats, whole wheat) instead.
Reduce Saturated Fat
Limit red meat, processed meats, butter, and full-fat dairy. Replace with healthier fats from fish, nuts, olive oil, and avocados.
Action: Choose lean proteins (chicken, fish, legumes) and plant-based fats.
Increase Omega-3 Fatty Acids
Omega-3s from fatty fish (salmon, mackerel, sardines) reduce liver inflammation and improve liver fat.
Action: Eat fatty fish 2-3 times per week, or consider omega-3 supplements.
Physical Activity
Regular exercise reduces liver fat, improves insulin sensitivity, and helps with weight loss.
Aerobic Exercise
150+ minutes per week of moderate activity (brisk walking, cycling, swimming)
Resistance Training
2-3 days per week to build muscle and improve metabolism
Reduce Sedentary Time
Break up sitting time with movement every 30-60 minutes
Control Metabolic Risk Factors
Diabetes / Prediabetes Management
Keep HbA1c below 7% (or as recommended by your doctor). High blood sugar promotes liver fat accumulation.
Action: Monitor blood sugar regularly, take medications as prescribed, follow a low-glycemic diet.
Cholesterol and Triglycerides
Manage dyslipidemia (high LDL, low HDL, high triglycerides) with diet and medications (statins are safe in MASLD).
Action: Target LDL <100 mg/dL, triglycerides <150 mg/dL, HDL >40 mg/dL (men) or >50 mg/dL (women).
Blood Pressure
Target <130/80 mmHg. High blood pressure is linked to worse liver outcomes in MASLD.
Action: Monitor daily, reduce sodium, take BP medications consistently.
Avoid Alcohol Completely
Even small amounts of alcohol can worsen liver damage in people with MASLD. Abstinence is strongly recommended, especially if you have MASH or fibrosis.
Medications for MASLD
While no drug is FDA-approved specifically for MASLD, several medications show promise for treating the condition:
GLP-1 Receptor Agonists (Semaglutide, Tirzepatide)
Originally for diabetes and weight loss, these medications reduce liver fat, improve inflammation, and may reverse MASH. Currently considered the most promising pharmacologic treatment.
Examples: Semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), liraglutide (Victoza, Saxenda)
Pioglitazone (Actos)
A diabetes medication that improves insulin sensitivity. Studies show it reduces liver inflammation (MASH) and may improve fibrosis.
Use: Considered for people with biopsy-proven MASH, especially those with diabetes. Side effects include weight gain and fluid retention.
Vitamin E
High-dose vitamin E (800 IU daily) can reduce liver inflammation in people with MASH who do NOT have diabetes.
Evidence: PIVENS trial showed improvement in liver histology. Not recommended for diabetics due to safety concerns.
SGLT2 Inhibitors
Diabetes medications that also promote weight loss and may reduce liver fat. Emerging evidence suggests liver benefits.
Examples: Empagliflozin (Jardiance), dapagliflozin (Farxiga), canagliflozin (Invokana)
Statins (for cholesterol)
Safe and recommended for cardiovascular protection in people with MASLD. Do NOT worsen liver disease despite older concerns.
Examples: Atorvastatin (Lipitor), rosuvastatin (Crestor)
Screening for Complications (if Cirrhosis)
Varices Screening
Enlarged veins in the esophagus (varices) can rupture and cause life-threatening bleeding. Screening with endoscopy recommended at diagnosis of cirrhosis.
Action: Upper endoscopy every 2-3 years if no varices, every 1-2 years if small varices present.
Liver Cancer Screening
Cirrhosis increases risk of hepatocellular carcinoma (HCC). Screening with ultrasound and AFP blood test every 6 months.
Action: Ultrasound + AFP every 6 months if cirrhosis confirmed.
Because MASLD is so common and often asymptomatic, screening is recommended for people with metabolic risk factors:
Type 2 Diabetes or Prediabetes
Up to 70% of people with type 2 diabetes have MASLD. Screen with FIB-4 score annually.
Metabolic Syndrome
If you have ≥3 criteria (high waist circumference, elevated triglycerides, low HDL, high BP, elevated fasting glucose), screen for MASLD.
Obesity
BMI ≥30 kg/m² (or ≥27.5 kg/m² for Asians). Risk increases with higher BMI and visceral (belly) fat.
Elevated Liver Enzymes
Unexplained elevation in ALT or AST warrants evaluation for MASLD after ruling out other liver diseases.
Imaging Showing Fatty Liver
If ultrasound, CT, or MRI incidentally shows fatty liver, assess metabolic risk factors and fibrosis risk.
Initial Screening Strategy: Calculate FIB-4 score for all at-risk individuals. If FIB-4 is intermediate or high (>1.3), proceed with elastography (FibroScan) or refer to hepatologist.
Use this checklist to guide your conversation about liver health:
MASLD affects 1 in 4 adults and is closely linked to diabetes, obesity, and metabolic syndrome
Liver enzymes (ALT, AST) may be NORMAL even with MASLD - don't rely on them alone
FIB-4 score is a simple, non-invasive way to assess fibrosis risk (ask your doctor to calculate it)
Weight loss is the most effective treatment: 5% reduces fat, 7-10% reverses MASH, >10% improves fibrosis
Mediterranean diet, avoiding fructose/sugary drinks, and regular exercise are cornerstones of treatment
GLP-1 agonists (like semaglutide) are the most promising medications for MASLD
Avoid alcohol completely to prevent worsening liver damage
If you have diabetes, obesity, or metabolic syndrome, ask to be screened for MASLD
Early detection and intervention can prevent progression to cirrhosis and liver failure
References:
1. Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023;79(6):1542-1556. doi:10.1016/j.jhep.2023.06.003
2. American Association for the Study of Liver Diseases (AASLD). Practice Guidance on the Clinical Assessment and Management of Nonalcoholic Fatty Liver Disease. Hepatology. 2023;77(5):1797-1835. doi:10.1097/HEP.0000000000000323
3. Loomba R, Friedman SL, Shulman GI. Mechanisms and disease consequences of nonalcoholic fatty liver disease. Cell. 2021;184(10):2537-2564. doi:10.1016/j.cell.2021.04.015
This guide translates clinical guidelines into patient-friendly language to help you understand and manage your liver health.